TrialLung cancer (Amsterdam, Netherlands)2025
Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.
Safoa Addo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.